Multimodality therapy for CNS mixed malignant germ cell tumors (MMGCT): results of a phase II multi-institutional study

✍ Scribed by Robertson, Patricia L.; Jakacki, Regina; Hukin, Juliette; Siffert, Joao; Allen, Jeffrey C.

• Book ID: 121647552
• Publisher: Springer US
• Year: 2014
• Tongue: English
• Weight: 314 KB
• Volume: 118
• Category: Article
• ISSN: 0167-594X
• DOI: 10.1007/s11060-013-1306-0

✦ Synopsis

In order to improve outcomes for CNS mixed malignant germ cell tumors (MMGCT) we sought to increase complete responses (CR) to initial therapy, through intensifying neoadjuvant chemotherapy (CHT1) with added ifosfamide, encouraging second-look surgery, and administering dose-intensive, stem cell-supported chemotherapy (CHT2) to patients with residual tumor, all prior to radiation therapy (RT). Diagnosis was confirmed by biopsy or elevated germ cell tumor markers. After tumor staging was completed, patients received four cycles of chemotherapy (cisplatin, etoposide and ifosfamide, "CHT1"). In patients with